What caused ALLO's Q1 2024 earnings to exceed forecasts?

Allogene Therapeutics Inc (ALLO) reported its Q1 2024 earnings with a surprise positive EPS surprise of $0.03 and a revenue surprise of $9830. ALLO's Q1 2024 earnings exceeded forecasts due to **Cost Management**.

|code|Ticker|Name|Date|Total Revenue|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|ALLO|ALLO.O|Allogene|2023 Q2|22000|-0.54|185|
|ALLO|ALLO.O|Allogene|2023 Q3|22000|-0.37|185|
|ALLO|ALLO.O|Allogene|2023 Q4|21000||185|
|ALLO|ALLO.O|Allogene|2024 Q1|22000|-0.38|185|

|code|Ticker|Name|Date|Total Revenue YoY|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|---|
|ALLO|ALLO.O|Allogene|2023 Q2|-74.4186046511628|-3.8461538461538494|185|
|ALLO|ALLO.O|Allogene|2023 Q3|-55.10204081632652|36.206896551724135|185|
|ALLO|ALLO.O|Allogene|2023 Q4|152.5||185|
|ALLO|ALLO.O|Allogene|2024 Q1|-26.666666666666668|44.927536231884055|185|

The company's ability to reduce costs and improve profit margins was a significant factor in the positive earnings surprise. Despite missing revenue estimates, the company's focus on cost management and improvement in profit margins led to a positive EPS surprise. This indicates that the company is effectively managing its resources and managing to beat expectations in terms of profitability.